Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced positive interim efficacy data from the Phase I stage of its ...
Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the“Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Company's Board of Directors approved the purchase of ...